These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27839923)

  • 1. Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes.
    Kosiborod M
    J Diabetes Complications; 2017 Feb; 31(2):517-519. PubMed ID: 27839923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The EMPA-REG study: What has it told us? A diabetologist's perspective.
    DeFronzo RA
    J Diabetes Complications; 2016; 30(1):1-2. PubMed ID: 26541076
    [No Abstract]   [Full Text] [Related]  

  • 3. EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives.
    Jørgensen NB; Pedersen J; Vaag AA
    J Diabetes Complications; 2016; 30(4):753. PubMed ID: 26970674
    [No Abstract]   [Full Text] [Related]  

  • 4. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
    Paty BW
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.
    Fisher M
    Diabetes Obes Metab; 2015 Apr; 17(4):335-42. PubMed ID: 25155010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.
    Owens DR; Monnier L; Hanefeld M
    Diabetes Obes Metab; 2017 Dec; 19(12):1645-1654. PubMed ID: 28474401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
    Fitchett D
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S176-82. PubMed ID: 26654861
    [No Abstract]   [Full Text] [Related]  

  • 9. Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial.
    Alzaid A
    Diabetes Technol Ther; 2017 Jun; 19(6):324-327. PubMed ID: 28300428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 inhibitors- A new age in lipid management?
    Grant PJ
    Diab Vasc Dis Res; 2017 May; 14(3):171. PubMed ID: 28467196
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
    Scheen AJ; Piérard L; Krzesinski JM; Paquot N
    Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.
    Ahmed HM; Khraishah H; Cho L
    Eur Heart J; 2018 Jul; 39(25):2368-2375. PubMed ID: 29236983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between the risk of cardiovascular disease in type 2 diabetes patients and both visit-to-visit variability and time-to-effect differences in blood pressure.
    Takao T; Kimura K; Suka M; Yanagisawa H; Kikuchi M; Kawazu S; Matsuyama Y
    J Diabetes Complications; 2015 Jul; 29(5):699-706. PubMed ID: 25861721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions.
    Roussel R; Steg PG; Mohammedi K; Marre M; Potier L
    Diabetes Obes Metab; 2018 Feb; 20(2):238-244. PubMed ID: 28597588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in Type 2 diabetes.
    Khunti K; Bellary S; Karamat MA; Patel K; Patel V; Jones A; Gray J; Shepherd P; Hanif W;
    Diabet Med; 2017 Jan; 34(1):64-68. PubMed ID: 26926478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
    Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
    Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.